Skip to main content

TARA

Stock
Health Care
Biotechnology

Performance overview

TARA Price
Price Chart

Forward-looking statistics

Beta
1.31
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Company info

SectorHealth Care
IndustryBiotechnology
Employees30
Market cap$55.0M

Fundamentals

Enterprise value-$3.2M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity2.67

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.49
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$2M
Put-call ratio—

Macro factor sensitivity

Growth-2.1
Credit+6.2
Liquidity+1.3
Inflation-5.2
Commodities-2.0
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-0.90
Price to sales—
P/E Ratio-0.90
Enterprise Value to Revenue—
Price to book0.70

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend day—

News

Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade

Protara Therapeutics (TARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (April 9, 2025)
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.

Benzinga (December 5, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free